Skip to Content

Akzo Nobel NV

AKZA: XAMS (NLD)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
€54.00ZrkxhbJynnnbsp

Another Profit Warning for AkzoNobel; Shares Still Materially Undervalued

Narrow-moat AkzoNobel announced third-quarter EBIT is expected to be EUR 195 million-EUR 215 million, implying a 15% drop over 2022 using the midpoint and a significant miss versus current Vara consensus of EUR 290 million. Despite the big consensus miss, shares are only down 1% intraday, which we think clearly indicates that true market consensus is much more bearish than current sell-side consensus. We have been consistently bearish versus sell-side consensus and management guidance. Nevertheless, 2022 is now looking worse than our previous conservative expectations. We have taken down our near-term estimates modestly, which only reduces our fair value estimate to EUR 100 from EUR 102. We continue to view the shares as materially undervalued.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of AKZA so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center